Akebia Therapeutics initiates Phase 2 trial of praliciguat for FSGS
Akebia Therapeutics is conducting Phase 2 trial to assess praliciguat's efficacy and safety in FSGS patients.
Phase II
Nephrology / Focal Segmental Glomerulosclerosis
Status
Active
Sponsor
Akebia Therapeutics
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of Phase 2 trial for praliciguat by Akebia Therapeutics is significant as it could reshape the competitive landscape for FSGS treatments. A successful outcome may enhance Akebia's market position and attract further investment and partnerships in the nephrology sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding efficacy and safety outcomes after the 24-week treatment period.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.